HIKMA PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,913 GBX | +3.18% |
|
+6.34% | +6.93% |
| Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets |  |
| Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,396 | 7,935 | 6,948 | 4,134 | 5,034 | 5,287 | - | - |
| Enterprise Value (EV) 1 | 6,638 | 8,540 | 7,368 | 5,147 | 6,010 | 6,142 | 5,897 | 5,690 |
| P/E ratio | 13.2 x | 19 x | 16.6 x | 22.5 x | 26.8 x | 12.5 x | 12.1 x | 11.9 x |
| Yield | 1.67% | 1.45% | 1.8% | 2.98% | 3.16% | 3% | 3.12% | 3.43% |
| Capitalization / Revenue | 2.9 x | 3.39 x | 2.72 x | 1.64 x | 1.75 x | 1.78 x | 1.72 x | 1.64 x |
| EV / Revenue | 3.01 x | 3.65 x | 2.89 x | 2.04 x | 2.09 x | 2.07 x | 1.92 x | 1.76 x |
| EV / EBITDA | 11.2 x | 12.7 x | 10.1 x | 7.42 x | 7.41 x | 7.73 x | 6.99 x | 6.35 x |
| EV / FCF | 18.8 x | 29.2 x | 14.9 x | 16.9 x | 14.9 x | 14.2 x | 12.1 x | 13.1 x |
| FCF Yield | 5.32% | 3.42% | 6.69% | 5.93% | 6.72% | 7.03% | 8.27% | 7.62% |
| Price to Book | 3.02 x | 3.72 x | 2.83 x | 1.94 x | 2.29 x | 2.1 x | 1.88 x | 1.68 x |
| Nbr of stocks (in thousands) | 242,278 | 230,458 | 231,442 | 220,230 | 221,080 | 221,885 | - | - |
| Reference price 2 | 26.40 | 34.43 | 30.02 | 18.77 | 22.77 | 23.83 | 23.83 | 23.83 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,203 | 2,341 | 2,553 | 2,517 | 2,875 | 2,972 | 3,075 | 3,234 |
| EBITDA 1 | 593 | 674 | 727 | 694 | 811 | 794.8 | 843.3 | 896.2 |
| EBIT 1 | 508 | 566 | 632 | 596 | 707 | 676.3 | 714.2 | 760.5 |
| Operating Margin | 23.06% | 24.18% | 24.76% | 23.68% | 24.59% | 22.76% | 23.22% | 23.52% |
| Earnings before Tax (EBT) 1 | 465 | 522 | 544 | 233 | 281 | 547.7 | 586.6 | 626.9 |
| Net income 1 | 486 | 431 | 421 | 188 | 190 | 419.2 | 450.6 | 475.4 |
| Net margin | 22.06% | 18.41% | 16.49% | 7.47% | 6.61% | 14.11% | 14.65% | 14.7% |
| EPS 2 | 2.000 | 1.811 | 1.807 | 0.8360 | 0.8500 | 1.902 | 1.968 | 1.998 |
| Free Cash Flow 1 | 353 | 292 | 493 | 305 | 404 | 431.7 | 487.7 | 433.3 |
| FCF margin | 16.02% | 12.47% | 19.31% | 12.12% | 14.05% | 14.53% | 15.86% | 13.4% |
| FCF Conversion (EBITDA) | 59.53% | 43.32% | 67.81% | 43.95% | 49.82% | 54.31% | 57.84% | 48.35% |
| FCF Conversion (Net income) | 72.63% | 67.75% | 117.1% | 162.23% | 212.63% | 102.98% | 108.25% | 91.16% |
| Dividend per Share 2 | 0.4400 | 0.5000 | 0.5400 | 0.5600 | 0.7200 | 0.7153 | 0.7438 | 0.8180 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,160 | 1,132 | 1,209 | 1,216 | 1,337 | 1,213 | 1,304 | 1,427 | 1,448 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | 282 | 309 | - | 296 | 300 | - | 306 |
| Operating Margin | - | - | 23.33% | 25.41% | - | 24.4% | 23.01% | - | 21.13% |
| Earnings before Tax (EBT) | - | - | 248 | - | - | - | - | - | - |
| Net income | - | - | 219 | - | - | - | - | - | - |
| Net margin | - | - | 18.11% | - | - | - | - | - | - |
| EPS | - | - | 0.9400 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 8/7/20 | 2/25/21 | 8/6/21 | 2/24/22 | 8/4/22 | 2/23/23 | 8/3/23 | 2/22/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 242 | 605 | 420 | 1,013 | 976 | 855 | 610 | 403 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.4081 x | 0.8976 x | 0.5777 x | 1.46 x | 1.203 x | 1.075 x | 0.7231 x | 0.4494 x |
| Free Cash Flow 1 | 353 | 292 | 493 | 305 | 404 | 432 | 488 | 433 |
| ROE (net income / shareholders' equity) | 19.1% | 20.3% | 18.4% | 17.7% | 22.7% | 19.3% | 18.9% | 18.8% |
| ROA (Net income/ Total Assets) | 9.8% | 10.7% | 9.9% | 9.18% | 10.8% | 9.91% | 10.2% | 10.3% |
| Assets 1 | 4,958 | 4,032 | 4,254 | 2,047 | 1,767 | 4,231 | 4,420 | 4,594 |
| Book Value Per Share 2 | 8.750 | 9.260 | 10.60 | 9.690 | 9.950 | 11.40 | 12.70 | 14.20 |
| Cash Flow per Share 2 | 1.940 | 1.950 | 2.740 | 2.360 | 2.730 | 2.840 | 3.280 | 3.430 |
| Capex 1 | 119 | 172 | 229 | 225 | 204 | 193 | 206 | 220 |
| Capex / Sales | 5.4% | 7.35% | 8.97% | 8.94% | 7.1% | 6.51% | 6.71% | 6.81% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
23.83
USD
Average target price
28.64
USD
Spread / Average Target
+20.20%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.93% | 5.29B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HIK Stock
- Financials Hikma Pharmaceuticals PLC
